Moore K A, Simpson J A, Pawet M K, et al. Safety of artemisinins in fi rst trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis 2016; 16: 576-83-In fi gure 4, the footnote symbols in the legend should have read '*Hazard ratios are shown for treatments occurring before (<6 weeks' gestation) and during (≥6 and <13 weeks' gestation) the embryosensitive window. †Artemisinin rescue after quinine failure refers to artemisinin-based treatment in fi rst trimester following failure of fi rst-line treatment with quinine or quinine plus clindamycin.' These corrections have been made to the online version as of April 18, 2016; the print version is correct.
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